Relief Therapeutics 报告了 EB 治疗 RLF-TD011 的有希望的初步结果，减少了有害细菌并改善了伤口愈合。 Relief Therapeutics reports promising preliminary results for EB treatment RLF-TD011, reducing harmful bacteria and improving wound healing.
Relief Therapeutics Holding SA 报告了 RLF-TD011 临床试验的有希望的初步结果，该试验针对一种罕见的遗传性皮肤病大疱性表皮松解症 （EB）。 Relief Therapeutics Holding SA has reported promising preliminary results from a clinical trial of RLF-TD011, targeting epidermolysis bullosa (EB), a rare genetic skin disorder. 治疗显示,EB伤口中的有害细菌黄金葡萄球菌显著减少,同时增强有益细菌并改善伤口愈合. The treatment showed significant reductions in Staphylococcus aureus, a harmful bacteria in EB wounds, while enhancing beneficial bacteria and improving wound healing. 美国食品和药物管理局已授予RLF-TD011孤儿药物名称,该公司计划寻求其他市场独家名称. The FDA has granted RLF-TD011 orphan drug designation, and the company plans to pursue additional market exclusivity designations.